PRTA241220C22500
- 0.05
- -0.05-50.00%
Prothena Newsroom
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
Prothena Stock Soars Despite Study Miss
Prothena Up Over 43%, On Pace for Largest Percent Increase Since September 2022 -- Data Talk
B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Express News | Prothena Corporation PLC : Oppenheimer Cuts Target Price to $58 From $62
Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease.
Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint
Express News | Roche’s Phase Iib Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Top Premarket Decliners
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62
Prothena Corp Analyst Ratings
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $24
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $84
JMP Securities Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $83
Prothena's Strategic Advancements and Financial Strength Underpin Buy Rating